Active — Not RecruitingNot Applicable

Anticoagulation in Patients With Venous Thromboembolism and Cancer

United Kingdom1 participantsStarted 2020-12-14

Plain-language summary

This study is a retrospective analysis of observational cohorts using data from prospectively collected administrative/claims data to investigate treatment patterns,healthcare resource utilisation (HCRU), direct and indirect costs (where feasible), and safety and effectiveness outcomes in patients with VTE and active cancer or patients with VTE and history of cancer who initiate anticoagulant treatment with a VKA, LMWH or NOACs.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * A VTE diagnosis * Active cancer or history of cancer * Treatment with VKA, NOAC (apixaban, rivaroxaban, dabigatran, edoxaban) or LMWH * Age ≥ 18 years at the date of index VTE (Venous thromboembolic) Exclusion Criteria: * Prior VTE diagnosis * Diagnosis of prior atrial fibrillation * Inferior Vena Cava (IVC) filter * Prior exposure to (OAC) oral anticoagulation or (PAC)parenteral anticoagulation - note: Prophylactic use of (OAC)/(PAC) allowed. * Pregnancy * More than one (OAC) oral anticoagulation or (PAC) parenteral anticoagulation dispensed on the index date. * Patients with less than one day of follow up

What they're measuring

Recurrence of Thromboembolism

Timeframe: 6 Months after treatment began as early as 1/1/2013

Trial details

NCT IDNCT04618913

SponsorPfizer

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2026-04-06

View on ClinicalTrials.gov More Neoplasms trials